Nutriband Inc.: Nutriband Subsidiary, 4P Therapeutics LLC, Conducts Phase 1b Clinical Study for Sorrento Therapeutics, Inc. on Lymphatic Etanercept Delivery in Rheumatoid Arthritis Patients With Results To Be Presented at the 2022 American College of Rheu

ORLANDO, FL / ACCESSWIRE / October 26, 2022 / Nutriband Inc. (the "Company") (NASDAQ:NTRB) (NASDAQ:NTRBW) today announced that its subsidiary, 4P Therapeutics LLC ("4P Therapeutics"), has conducted a Phase

Related Keywords

Mexico ,Georgia ,United States ,Australia ,Japan ,Atlanta ,Russia ,Canada ,American ,Sorrento Sofusa ,Alan Smith ,Semnur Pharmaceuticals Inc ,Drug Administration ,American College Of Rheumatology ,Nasdaq ,Exchange Commission ,Company Form ,Sorrento Therapeutics Inc ,Pivotal Trialc Le Ar Program ,Nutriband Inc View ,Scilex Pharmaceuticals Inc ,Nutriband Inc ,Redchip Companies ,P Therapeutics ,Sorrento Therapeutics ,American College ,Etanercept Achieves Significant Improvements ,Rheumatoid Arthritis Disease Measures ,Standard Dose ,Inadequate Response ,Subcutaneous Injections ,United States Food ,Sofusa Business Unit ,Private Securities Litigation Reform Act ,Federal Food ,Financial Condition ,Annual Report ,Quarterly Reports ,Semnur Pharmaceuticals ,Scilex Pharmaceuticals ,Nutriband ,Ubsidiary ,Herapeutics ,Onducts ,Hase ,Linical ,Study ,Orrento ,Glymphatic ,Etanercept ,Delivery ,Rheumatoid ,Arthritis ,Patients ,Ith ,Results ,Resented ,022 ,College ,Mh ,